(Q37756597)

22 August 2017

1 reference

title

The use of PTH in the treatment of osteoporosis (English)

1 reference

22 August 2017

0 references

Victória Z Cochenski Borba

series ordinal

1

1 reference

22 August 2017

Nádila Cecyn Pietszkowski Mañas

series ordinal

2

1 reference

22 August 2017

publication date

1 March 2010

1 reference

Arquivos Brasileiros de Endocrinologia e Metabologia

22 August 2017

published in

1 reference

22 August 2017

volume

54

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

213-219

1 reference

Treatment of osteoporosis with parathyroid hormone and teriparatide

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Anabolic skeletal therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Bone-forming agents in the management of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Management of glucocorticoids-induced osteoporosis: role of teriparatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Molecular and cellular mechanisms of the anabolic effect of intermittent PTH

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Improvements in Vertebral Body Strength Under Teriparatide Treatment Assessed In Vivo by Finite Element Analysis: Results From the EUROFORS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Improvement in health-related quality of life in osteoporosis patients treated with teriparatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Clinical update on teriparatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Teriparatide reduces bone microdamage accumulation in postmenopausal women previously treated with alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Safety of parathyroid hormone for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

PTH-analogs: comparable or different?

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-27302010000200018

10.1590/S0004-27302010000200018

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4yyfowx76rhg5gwh7dwh76tkay

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_4yyfowx76rhg5gwh7dwh76tkay

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4yyfowx76rhg5gwh7dwh76tkay

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/4yyfowx76rhg5gwh7dwh76tkay

1 reference